Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 79
Selected: 0
NCT IDTitle
NCT02415023A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
NCT04923932Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT00659802Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT06437353Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT01985555Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT02689752A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT05009836Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT00655733Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT03976856Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
NCT02374645A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT03597971HMPL004-6599 Phase I Dose-escalating Study
NCT01882764HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
NCT01645215Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
NCT03483259To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
NCT02590952A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
NCT02857998A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
NCT04272957A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT05015621A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
NCT03684967Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
NCT03860532Phase I Clinical Trial in Healthy Male Volunteers
NCT02252913A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer
NCT02966171A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
NCT05511051A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
NCT02588170Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
NCT04290325HMPL-453 in Advanced Malignant Mesothelioma
NCT04755075Surufatinib Hepatic Impairment Study
NCT02589821Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
NCT03091192Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT02691299A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
NCT01805791A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
NCT03951623The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
NCT01955304Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects
NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
NCT02314819A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT04716634Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
NCT05842525Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT02196688Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT02590965A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
NCT04372407A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
NCT02017236A Food Effect Phase I Study of the Volitinib in Healthy Subjects
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects